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Highlights 
 Vitamin D deficiency is common among UK adults with ICS-treated asthma 
 Classical environmental determinants of vitamin D status operate in this population 
 Vitamin D status did not associate with markers of asthma severity or control 
 Genetic variation in the vitamin D pathway did not influence vitamin D status or measures of 
asthma severity or control 
 
Abstract 
 
Vitamin D deficiency is common in children with asthma, and it associates with poor asthma control, 
reduced forced expiratory volume in one second (FEV1) and increased requirement for inhaled 
corticosteroids (ICS). Cross-sectional studies investigating the prevalence, determinants and clinical 
correlates of vitamin D deficiency in adults with asthma are lacking. We conducted a multi-centre cross-
sectional study in 297 adults with a medical record diagnosis of ICS-treated asthma living in London, UK. 
Details of potential environmental determinants of vitamin D status, asthma control and medication use 
were collected by questionnaire; blood samples were taken for analysis of serum 25(OH)D concentration 
and DNA extraction, and participants underwent measurement of weight, height and fractional exhaled 
nitric oxide concentration (FeNO), spirometry and sputum induction for determination of lower airway 
eosinophil counts (n=35 sub-group). Thirty-five single nucleotide polymorphisms (SNP) in 11 vitamin D 
pathway genes (DBP, DHCR7, RXRA, CYP2R1, CYP27B1, CYP24A1, CYP3A4 CYP27A1, LRP2, CUBN, VDR) were 
typed using Taqman allelic discrimination assays. Linear regression was used to identify environmental and 
genetic factors independently associated with serum 25(OH)D concentration, and to determine whether 
vitamin D status was independently associated with Asthma Control Test (ACT) score, ICS dose, FeNO, 
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forced vital capacity (FVC), FEV1 or lower airway eosinophilia. Mean serum 25(OH)D concentration was 50.6 
nmol/L (SD 24.9); 162/297 (54.5%) participants were vitamin D deficient (serum 25(OH)D concentration <50 
nmol/L). Lower vitamin D status was associated with higher body mass index (P=0.014), non-White ethnicity 
(P=0.036), unemployment (P for trend =0.012), lack of vitamin D supplement use (P<0.001), sampling in 
Winter or Spring (P for trend <0.001) and lack of a recent sunny holiday abroad (P=0.030), but not with 
potential genetic determinants. Vitamin D status was not found to associate with any marker of asthma 
control investigated. Vitamin D deficiency is common among UK adults with ICS-treated asthma, and 
classical environmental determinants of serum 25(OH)D operate in this population. However, in contrast to 
studies conducted in children, we found no association between vitamin D status and markers of asthma 
severity or control. 
 
Keywords 
Vitamin D, asthma, phenotype, environmental, cross-sectional, genetics. 
 
1. Introduction 
 
Vitamin D deficiency has been reported to be common among children with asthma in diverse settings, and 
to associate with reduced forced expiratory volume in one second (FEV1), poor asthma control and 
increased requirement for inhaled corticosteroids (ICS) (1-5). Despite the high prevalence of both asthma 
and vitamin D deficiency among adults in the industrialised world, cross-sectional studies assessing the 
prevalence, determinants and clinical correlates of vitamin D deficiency in adults with asthma have not 
previously been performed in such settings to our knowledge. Moreover, despite evidence suggesting that 
genetic variation can influence vitamin D status in the general population (6), studies to quantify the 
relationship between single nucleotide polymorphisms (SNP) in the vitamin D pathway and serum 25-
hydroxyvitamin D (25[OH]D) concentrations (the accepted biomarker of vitamin D status), or clinical 
correlates of asthma phenotype, have not previously been performed in patients with asthma. 
 
We therefore conducted a cross-sectional study to assess the prevalence of vitamin D deficiency in a group 
of adults with ICS-treated asthma in London, UK, and to explore environmental and genetic determinants of 
vitamin D status in this group. We also conducted analyses to determine whether serum 25(OH)D 
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concentration or genetic variation in the vitamin D pathway associated with markers of asthma control in 
this population, including symptom control, FEV1, forced vital capacity (FVC), ICS requirement and fractional 
exhaled nitric oxide concentration (FeNO). Additional analyses were performed to determine whether 
serum 25(OH)D concentration and genetic variants in the vitamin D pathway interacted to influence asthma 
control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Methods 
 
2.1. Participants  
 
Adult patients with a medical record diagnosis of asthma treated with ICS were identified by searching 
databases at 60 general practices and at asthma clinics in 2 Acute National Health Service Trusts in London, 
UK, and invited for screening as previously described (7). The study was approved by East London and The 
City Research Ethics Committee 1 (ref 09/H0703/67) and written informed consent was obtained from all 
participants before enrolment. 
 
2.2. Procedures 
 
Respondents were asked to complete a lifestyle questionnaire detailing age, sex, ethnicity, self-reported 
Fitzpatrick skin-type (8), self-classified socio-economic position (SEP) using the National Statistics – Socio-
Economic Classification (NS-SEC) method (9), daily hours spent outdoors, history of recent sunny holidays 
abroad (defined as a trip to any location within a latitude 51o North/South of the equator, during the local 
sunny season, 2 months prior to blood draw, for a duration of ≥1 week), smoking behaviour and 
consumption of alcohol and supplemental vitamin D. Respondents also completed the asthma control test 
(ACT) questionnaire (10), and underwent a baseline clinical assessment including the following: spirometry 
before and after inhalation of 400 μg salbutamol via a spacer device, performed using a MicroLab ML3500 
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desktop spirometer (CareFusion GmbH, Hoechberg, Germany) according to American Thoracic Society (ATS) 
/ European Respiratory Society (ERS) recommendations (11); FeNO measurement, performed using a NIOX 
MINO 09-1100 (Aerocrine, Solna, Sweden) according to ATS / ERS recommendations (12); height 
measurement (using a Seca 220 Telescopic Measuring Rod, Seca, Hamburg, Germany), and weight 
measurement (using Marsden MMPS-250 column scales, Marsden, Rotherham, UK]). A blood sample was 
collected for DNA extraction and determination of serum concentration of total 25[OH]D and parathyroid 
hormone (PTH). A sub-set of 35 participants underwent sputum induction with hypertonic saline, and their 
samples were processed to make cytospin slides according to methods described by Pizzichini et al (13). 
Differential cell counts were performed by one operator for all specimens throughout the study; a second 
operator repeated cell counts on a randomly selected sub-set of 20 slides: differential cell counts were 
highly correlated between operators (for eosinophil count, Pearson’s r =0.95, 95% CI 0.87 to 0.98, P<0.001). 
 
2.3. Single nucleotide polymorphism panel selection 
 
A literature search of the PubMed database was performed to identify SNP previously shown to associate 
with serum 25(OH)D concentration or non-skeletal disease outcomes, which is described elsewhere (14). 
We identified 55 such SNP in 11 genes in the vitamin D pathway. Based on linkage disequilibrium (LD) 
relationships between these SNP, we selected 6 tagging SNP (tSNP) (15), using a r2 threshold of 0.8, which 
reduced the number of SNP genotyped to 37. 
 
2.4. Laboratory analyses 
 
Serum concentrations of 25(OH)D2 and 25(OH)D3 were determined by isotope-dilution liquid 
chromatography–tandem mass spectrometry (16) in the Department of Clinical Biochemistry at Homerton 
Hospital, and summed to give total serum 25(OH)D concentration. This laboratory participates in the 
international vitamin D external quality assurance scheme (www.deqas.org/). PTH concentrations were 
determined using an Architect ci8200 analyser (Abbott Diagnostics, Chicago, IL, USA). DNA was extracted 
from whole blood using a salting-out method (17) on the Biomek FX robot (Beckman Coulter), quantified 
using the Nanodrop spectrophotometer and normalised to 5ng/µl.  10ng DNA were used as template for 2 
µl TaqMan assays (Applied Biosystems, Foster City, CA, USA) performed on the ABI 7900HT platform in 384-
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well format and analysed with Autocaller software as previously described (7). Typing for two SNP failed 
(rs6127118, CYP24A1 and rs11574010, VDR). 
 
2.5. Statistical analyses 
 
Using STATA 12 we performed unpaired Student’s T tests or one-way ANOVA tests on normally distributed 
dependent variables (serum 25[OH]D concentration, % predicted FEV1, and % predicted FVC) and Mann-
Whitney or Kruskal-Wallis tests on non-normally distributed dependent variables (ACT score, FeNO readings, 
sputum eosinophilia levels, ICS dose) to identify independent correlates of serum 25(OH)D concentration, 
vitamin D pathway SNP and measures of asthma control on univariate analysis. All dependent variables 
were continuous. Non-normally distributed dependent variables were transformed to their natural 
logarithms. All factors with a minimum of 5 participants per outcome were fitted in multiple linear 
regression models to give adjusted coefficients, along with a 95% confidence interval and a P value for 
pairwise association in variables with 2 categories, or a P value for trend where in variables with ≥3 
categories. For the analyses exploring associations between vitamin D pathway SNP and clinical correlates of 
asthma phenotype, a P value for the interaction between SNP genotype and baseline vitamin D status was 
also generated. In the case of log-transformed dependent variables, the anti-log of the adjusted regression 
coefficient is presented. Genetic analyses were adjusted for all putative environmental determinants of 
serum 25(OH)D concentration (for n=15 SNP previously found to associate with vitamin D status), or clinical 
correlates of asthma phenotype (for n=35 SNP previously found to associate with vitamin D status and/or 
non-skeletal disease outcomes) that were investigated. Multiple comparison testing was then applied using 
the Benjamini & Hochberg method with a false discovery rate (FDR) of 5% (18). All environmental and 
genetic independent variables were classified as categorical variables. All SNP were analysed under an 
additive model.  
 
3. Results 
 
3.1. Study population 
 
A total of 297 adults with a medical record diagnosis of ICS-treated asthma were enrolled in the study 
between 27th August 2009 and 25th June 2012. All consented to undergo clinical measurements and to 
donate blood samples for quantification of serum 25(OH)D and PTH concentration; all but one agreed to 
7 
 
donate a blood sample for DNA storage and genotyping. Participant characteristics are presented in Table 1. 
Age range was 16-78 years, with a mean of 48.7 years (SD 14.4). Most participants (57.2%) were female. The 
majority of participants (82.5%) classified their ethnic origin as White; 8.5% classified their ethnic origin as 
Black/Black British, 5.7% as Asian/Asian British, and 3.0% as being of mixed ethnicity. 261/297 (87.9%) 
participants’ asthma was managed exclusively in primary care. Mean serum 25(OH)D concentration for all 
participants was 50.6 nmol/L (SD 24.9). Forty participants (13.5%) had serum 25(OH)D concentration <25 
nmol/L; 122 (41.1%) had serum 25(OH)D concentration 25 - 49.9 nmol/L; 80 (26.9%) had serum 25(OH)D 
concentration 50 – 74.9 nmol/L; and only 55 (18.5%) had serum 25(OH)D concentration ≥ 75 nmol/L. 
 
3.2. Environmental determinants of serum 25(OH)D concentration 
 
Environmental determinants of vitamin D status are presented in Table 2 and Figure 1. Multiple linear 
regression analysis showed the following factors to independently associate with lower serum 25(OH)D 
concentration: higher BMI (adjusted mean difference of 7.2 nmol/L for BMI of ≥25 kg/m2vs. <25 kg/m2; 95% 
CI -13.0 to -1.5 nmol/L; P=0.014); non-White Ethnicity (adjusted mean difference 13.3 nmol/L for White vs. 
non-White; 95% CI -25.8 to -0.9 nmol/L; P=0.036); lower SEP (greatest adjusted mean difference 19.6 
nmol/L for SEP groups 1/2 vs. Unemployed; 95% CI -36.8 to -2.5 nmol/L; P for trend = 0.012); lack of vitamin 
D supplement consumption (adjusted mean difference 21.5 nmol/L for those taking a dose of any size vs. 
those taking no vitamin D supplement; 95% CI -28.7 to -14.2 nmol/L; P<0.001); sampling in Winter or Spring 
(greatest adjusted mean difference 18.5 nmol/L for those sampled in Quarter 3 vs. Quarter 1; 95% CI -26.2 
to -10.8 nmol/L, P for trend <0.001); lack of a recent sunny holiday (adjusted mean difference 7.7 nmol/L for 
those who took one in the previous 2 months vs. those who did not; 95% CI -14.7 to -0.8 nmol/L; P=0.030); 
and BTS treatment step (adjusted mean difference 8.1 nmol/L for groups 2/3 vs. 4/5; 95% CI -16.0 to -0.3 
nmol/L; P=0.043). 
  
3.3. Genetic determinants of serum 25(OH)D concentration 
 
Genetic determinants of vitamin D status are presented in Table 3. After adjusting for sex, age, BMI, 
ethnicity, SEP, number of hours spent outdoors, vitamin D supplement consumption, season of blood draw, 
Fitzpatrick skin-type, smoking status, alcohol consumption, tanning bed use, recent sunny holiday, and BTS 
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treatment step, and correcting for multiple comparison testing, none of the 15 SNP investigated were found 
to associate independently with serum 25(OH)D concentration. 
 
3.4. Association between vitamin D status and asthma phenotype 
 
Clinical determinants of vitamin D status are presented in Table 4. After adjustment for potential 
confounders, we found no relationship between vitamin D status and asthma phenotype. Specifically, we 
found no statistically significant independent association between serum 25(OH)D concentration and 
Asthma Control Test score (Table S1), % predicted FEV1 (Table S2), % predicted FVC (Table S3), inhaled 
corticosteroid dose (Table S4), FeNO (Table S5) or induced sputum eosinophilia (Table S6; n=35 sub-set of 
participants). However, multiple linear regression analysis did show other factors to associate with these 
various aspects of asthma phenotype. Poor asthma control, as indicated by lower ACT scores, was 
independently associated with lower alcohol consumption (P for trend = 0.003), BMI ≥25kg/m2 (P=0.026), 
non-White ethnicity (P<0.001) and lower SEP (P for trend = 0.018; Table S2). Older age and non-White 
ethnicity associated with decreased % predicted FEV1 (P<0.001 for both factors, Table S3). Alcohol 
consumption and previous pneumococcal vaccination associated independently with increased ICS dose 
(P=0.03 for both factors, Table S4). Decreased FeNO levels were associated with female sex (P<0.001) and 
history of current smoking (P=0.040, Table S5), while sputum eosinophilia was positively correlated with 
peripheral blood eosinophilia (P=0.013, Table S6). 
 
3.5. Association between genetic factors and asthma phenotype 
 
Genetic determinants of clinical correlates of asthma phenotype are presented in Table S7 (% predicted 
FEV1), Table S8 (% predicted FVC), Table S9 (FeNO), Table 10 (ACT), and Table S11 (ICS). After correcting for 
multiple comparison testing none of the genetic factors which independently associated with markers of 
asthma phenotype as main effects, or by interaction with baseline vitamin D status, remained significant. 
 
4. Discussion 
To our knowledge, this study represents the largest cross-sectional investigation of vitamin D status in 
adults with asthma conducted to date, and the first such study to explore the influence of both genetic and 
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environmental determinants of vitamin D status in this patient group. Vitamin D deficiency, defined using 
the 50 nmol/L 25(OH)D threshold, was present in the majority of participants, and it associated with 
classical environmental determinants of vitamin D status, but not with any potential genetic determinant 
investigated. No association was found between vitamin D status or vitamin D pathway SNP and a broad 
range of measures of asthma control including symptom score, % predicted FEV1, % predicted FVC, ICS 
requirement and FeNO concentration. The lack of association between vitamin D genotype and the outcome 
measures we investigated may reflect a small impact from genetic variation in this particular population. 
 
Our findings with respect to prevalence of environmental determinants of vitamin D status are in keeping 
with those previously reported for other UK populations without asthma (19). By contrast, our finding of a 
lack of association between serum 25(OH)D concentrations and asthma phenotype - supported by the lack 
of association between vitamin D pathway SNP and asthma phenotype we observed - conflicts with the 
other studies in the literature, which have variously reported associations between lower vitamin D status 
and worse asthma control, more severe disease, lower % predicted FEV1 and increased requirement for 
inhaled corticosteroids (1, 2, 4, 5, 20-22).  
 
Why might our findings differ? First, the majority of studies in the literature have investigated children with 
more severe asthma (1-5, 23, 24) while our study is in adults with generally better symptom control. It may 
be that asthma phenotype is more readily modified by vitamin D in paediatric populations, and/or in those 
with more severe asthma: in keeping with the former hypothesis, randomised controlled trials of vitamin D 
supplementation to improve asthma control have tended to show protective effects in children (25, 26), but 
not in adults (7, 27). A second potential explanation is that residual confounding may have contributed to 
the finding of positive associations in other studies: we collected detailed information on potential 
confounders of the relationship between vitamin D status and asthma control and adjusted for them in 
multivariable analyses. A third possibility is that publication bias may have contributed to the dearth of null 
studies in the published literature. 
 
Our analysis of other determinants of asthma phenotype identified a number of expected predictors, but 
also revealed some new information. The association between increased alcohol consumption and 
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improved asthma control is intriguing: a negative association between maternal alcohol consumption and 
risk of asthma in offspring has been previously reported (28). More research is needed to understand the 
relationship between alcohol intake and asthma control, and to identify potential mechanisms of protection 
if applicable. Our finding of an independent association between poorer asthma control and non-White 
ethnicity chimes with other reports (29, 30); the fact that serum 25(OH)D did not associate with ACT score in 
this analysis suggests that lower vitamin D status does not account for such ethnic differences in asthma 
control. 
 
4.1. Study strengths 
 
Our study has several strengths. We investigated a wide range of potential environmental and genetic 
determinants of vitamin D status and asthma control, recorded detailed information on potential 
confounders of the relationship between 25(OH)D and asthma control, and phenotyped patients in 
considerable detail: spirometry and measurement of FeNO were performed using international guidelines 
and serum 25(OH)D concentrations were measured with the gold standard assay (LC-MS/MS) in a laboratory 
that participated in the international vitamin D external quality assurance scheme (www.deqas.org/). The 
study population included patients with mild, moderate and severe disease from both community and 
hospital settings, studied across all seasons: these features enhance generalisability of our results. 
 
4.2. Study limitations 
 
Our study also has some limitations. A minority of participants had serum 25(OH)D concentrations >75 
nmol/L, so we may have been underpowered to detect effects of the highest 25(OH)D concentrations on 
asthma phenotype: our results do not therefore definitively preclude beneficial effects of elevating serum 
25(OH)D to >75 nmol/L. However, our findings are in keeping with clinical trials of vitamin D 
supplementation in adults, which have been null to date with respect to asthma control indices (7, 27). Lack 
of effects for vitamin D on asthma control outcomes in these trials may reflect a lack of power, low 
prevalence of profound vitamin D deficiency at baseline, and / or sub-optimal dosing regimens; they do not 
exclude protective effects of vitamin D on risk of asthma exacerbation, as discordance between 
physiological measures of asthma control and exacerbation risk are well recognised (31); indeed, a recent 
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meta-analysis of randomised controlled trials of vitamin D supplementation revealed a protective effect of 
vitamin D against severe asthma exacerbation, but no effect on day-to-day symptom control (32)  
 
In conclusion, we report that vitamin D deficiency is common in a UK adult population with ICS-treated 
asthma, and that this is influenced by the same classical environmental determinants of vitamin D status 
that operate in the general population. However, in this population genetic factors did not have a strong 
influence on vitamin D status, or on measures of asthma control. 
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Figure 1: Environmental determinants of vitamin D status in adults with ICS-treated asthma. Lower serum 25-
hydroxyvitamin D (25[OH]D) concentrations were associated with higher body mass index (A), non-white ethnicity 
(B), lower socio-economic position (C), lack of vitamin D supplement use (D), sampling in Winter or Spring (E) and 
lack of a recent sunny holiday (F). Error bars represent median and interquartile ranges. P values are from linear 
regression adjusting for all potential environmental determinants of vitamin D status. 
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Table1: Participant Characteristics (N=297) 
Sex, n (%) Female 170 (57.2) 
 Male 127 (42.8) 
Mean Age, yrs (SD)   48.7 (14.4) 
Mean BMI, kg/m2 (SD)  27.6 (5.9) 
Ethnicity, n (%) 1 White 245 (82.5) 
 Asian / Asian British 17 (5.7) 
 Black / Black British 25 (8.5) 
 Mixed 9 (3.0) 
Fitzpatrick skin type, n (%) 2 1 19 (6.4) 
 2 57 (19.2) 
 3 127 (42.8) 
 4 57 (19.2) 
 5  25 (8.4) 
 6  12 (4.0) 
Socio-economic position, n (%) 3 1 199 (67.0) 
 2 29 (9.8) 
 3 29 (9.8) 
 4 12 (4.0) 
 5 15 (5.0) 
 Student 6 (2.0) 
 Unemployed 7 (2.4) 
Time outdoors per day, n (%) >2hrs 103 (34.7) 
 ≤2hrs 194 (65.3) 
Vitamin D supplement, IU/day, n (%)4 Any 48 (16.2) 
 None 242 (81.5) 
Quarter of blood draw, n (%) Q1 (January – March) 88 (29.6) 
 Q2 (April – June) 78 (26.3) 
 Q3 (July – September) 60 (20.2) 
 Q4 (October – December) 71 (23.9) 
Smoking status, n (%) Non-current 279 (93.9) 
 Current 18 (6.1) 
Mean alcohol intake, units/week (SD)5  10.2 (11.7) 
Tanning bed use in previous year, n (%) Yes 19 (6.4) 
 No 278 (93.6) 
Recent sunny holiday, n (%) 6 Yes 52 (17.8) 
 No 240 (82.2) 
BTS step of treatment, n (%) 2: Regular preventer therapy 134 (45.1) 
 3: Initial add-on therapy 125 (42.1) 
 4: Persistent poor control 35 (11.8) 
 5: Continuous / frequent use of OCS 3 (1.0) 
Managed exclusively in primary care, n (%)  261 (87.9) 
Medication use Mean ICS dose at entry in beclometasone 
equivalents, µg (SD) 7 
725.3 (631.2) 
Inhaled LABA use, n (%) 8 155 (52.2) 
Leukotriene antagonist use, n (%) 33 (11.1) 
Mean % predicted FEV1 (SD)  82.4 (20.3) 
Mean FeNO, ppb (SD)  36.2 (26.4) 
Mean serum corrected calcium (SD)  2.23 (0.08) 
Mean serum PTH (SD)  5.7 (3.9) 
Serum PTH >6.8 pmol/L, n (%) Yes 71 (23.9) 
 No 226 (76.1) 
Serum 25(OH)D, nmol/L (%) <25 40 (13.5) 
 25 – 49.9 122 (41.1) 
 50 – 74.9 80 (26.9) 
 ≥ 75 55 (18.5) 
Mean serum 25(OH)D, nmol/L (SD)  50.6 (24.9) 
[1]Ethnicity not reported in n=1. Mixed ethnicity: n=6 White and Black Caribbean, n=1 British Mauritian, n=1 Asian Caribbean, n=1 
Irish Sri Lankan. [2] Fitzpatrick skin-type scores:  1 = extremely fair skin; always burn, never tan, 2 = fair skin; always burn, sometimes 
tan, 3 = pale skin; sometimes burn, always tan, 4 = olive skin; rarely burn, always tan, 5 = moderately pigmented brown skin; never 
burn, always tan, 6 = markedly pigmented black skin; never burn, always tan.[3] SEP classes: 1 = managerial, administrative and 
professional occupations, 2 = intermediate occupations, 3 = small employers and own account workers, 4 = lower supervisory and 
technical occupations, 5 = semi-routine and routine occupations, 6 = student, 7 = Never/Long-term (>5yrs) unemployed.[4] Vitamin D 
supplement consumption not reported in n=7.[5] One alcohol unit = 8g pure alcohol.[6]Recent sunny holiday not reported in n=5.[7] 1µg 
beclometasone assumed equivalent to 1µg budesonide, 0.5 mcg fluticasone dipropionate and 0.75 mcg ciclesonide.[8]Includes 
combinations of ICS/LABA and LABA  
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Table 2: Environmental determinants of vitamin D status 
        
  N Serum 25(OH)D, nmol/L  Univariate              
P value 7 
Multivariable model -   
Beta Coefficient (95% CI) 
P value 8 
   Mean (SD) Mean 
difference 
   
Sex Female 170 50.7 (26.1) referent 0.96 referent 0.13 
 Male 127 50.5 (23.2) -0.2  -4.4 (-10.1 to 1.4)  
Age quartiles 1 (16.0 – 37.7 yrs) 74 52.5 (25.4) referent 0.26 referent 0.54† 
 2 (37.8 – 49.6 yrs) 74 48.4 (25.0) -4.1  -0.8 (-8.8 to 7.1)  
 3 (49.7 – 60.5 yrs) 74 47.2 (22.2) -5.3  -0.5 (-8.5 to 7.5)  
 4 (60.6 – 79.0 yrs) 75 54.3 (26.4) +1.8  +2.6 (-5.6 to 10.8)  
BMI, kg/m2 <25 113 56.8 (26.2) referent <0.001 referent 0.014 
 ≥25 184 46.8 (23.2) -10.0  -7.2 (-13.0 to -1.5)  
Ethnicity1 White 245 53.3 (25.5) referent <0.001 referent 0.036 
 Non-white  51 37.7 (16.8) -15.6  -13.3 (-25.8 to -0.9)  
SEP 2 1,2 228 51.0 (24.9) referent 0.099 referent 0.012† 
 3,4,5 56 51.8 (24.6) +0.8  +4.9 (-2.0 to 11.8)  
 Student 6 49.0 (30.0) -2.0  -6.3 (-24.9 to 12.4)  
 Unemployed 7 27.6 (10.3) -23.4  -19.6 (-36.8 to -2.5)  
Hours spent 
outdoors/day 
>2 103 56.7 (26.9) referent 0.002 referent 0.17 
≤2 194 47.4 (23.2) -9.3  -4.1 (-9.8 to 1.7)  
Vitamin D supplement, 
IU/day3 
Any 48 68.5 (24.8) referent <0.001 referent <0.001 
None 242 47.4 (23.5) -21.1  -21.5 (-28.7 to -14.2)  
Quarter of blood draw Q1 (January – March) 88 42.2 (23.6) -17.7 <0.001 -18.5 (-26.2 to -10.8) <0.001† 
Q2 (April – June) 78 52.5 (27.1) -7.4  -11.0 (-19.0 to -3.0)  
Q3 (July – September) 60 59.9 (24.2) referent  referent  
Q4 (October – December) 71 51.0 (21.2) -8.9  -13.5 (-21.6 to -5.4)  
Fitzpatrick skin-type 4 1,2 76 48.7 (24.4) -5.3 <0.001 -4.4 (-10.6 to 1.9) 0.81† 
 3,4 184 54.0 (25.4) referent  referent  
 5,6 37 37.6 (17.9) -16.4  -2.4 (-16.7 to 11.8)  
Smoking status Non-current 279 50.1 (24.6) referent 0.22 referent 0.92 
 Current 18 57.5 (28.8) +7.4  -0.6 (-12.3 to 11.0)  
Alcohol consumption, 
units/wk 
0 51 45.0 (23.4) referent 0.21 referent 0.25† 
1-20 198 51.7 (24.8) +6.7  +5.7 (-1.9 to 13.2)  
>20 48 52.0 (26.2) +7.0  +5.8 (-4.1 to 15.7)  
Tanning bed use, 
previous year 
Yes 19 62.3 (17.9) referent 0.033 referent 0.19 
No 278 49.8 (25.1) -12.5  -7.4 (-18.5 to 3.8)  
Recent sunny holiday 5 Yes 52 58.6 (30.0) referent 0.012 referent 0.030 
 No 240 49.0 (23.5) -9.6  -7.7 (-14.7 to -0.8)  
BTS treatment step6 2/3 259 50.2 (24.0) -3.1 0.47 -8.1 (-16.0 to -0.3) 0.043 
 4/5 38 53.3 (30.4) referent  referent  
[1]Ethnicity not reported in n=1. Other ethnicities: n=17 Asian, n=25 Black, n=9 Mixed ethnicity. One participant declined to report ethnicity.  
[2] Socio-economic Position (SEP) classes: 1 = managerial, administrative and professional occupations, 2 = intermediate occupations, 3 = small employers and 
own account workers, 4 = lower supervisory and technical occupations, 5 = semi-routine and routine occupations, 6 = student, 7 = Never/Long-term (>5yrs) 
unemployed. 
[3]Vitamin D supplement consumption not reported in n=7. 
[4]Fitzpatrick skin-type scores:  1 = extremely fair skin; always burn, never tan, 2 = fair skin; always burn, sometimes tan, 3 = pale skin; sometimes burn, always 
tan, 4 = olive skin; rarely burn, always tan, 5 = moderately pigmented brown skin; never burn, always tan, 6 = markedly pigmented black skin; never burn, 
always tan. 
[5]Recent sunny holiday not reported in n=5. 
[6] BTS treatment step definitions: 2. Regular preventer therapy, 3. Initial add-on therapy, 4. Persistent poor control, 5. Continuous / frequent use of OCS 
[7]Univariate method: Student’s T-test/One-way ANOVA 
[8]Adjusted for all investigated potential determinants of 25(OH)D concentration : Sex, age, BMI, ethnicity, SEP, hours outdoors, vitamin D supplementation, 
quarter of blood draw, skin-type, smoking status, alcohol consumption, tanning bed use, recent sunny holiday, British Thoracic Society treatment step. 
†P-value for trend 
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Table 3: Genetic determinants of vitamin D status 
 
Gene SNP Genotype N Serum 25(OH)D, nmol/L  Multivariable model -   
Beta Coefficient (95% CI) 
P value for 
trend 1 
    Mean (SD) Mean 
difference 
   
CYP24A1 
  
  
  
  
  
rs6013897 
  
  
TT 174 53.5 (26.6) referent referent 0.13 
AT 96 47.0 (22.5) -6.5 -3.6 (-9.2 to 2.0)   
AA 14 41.9 (19.3) -11.6 -9.4 (-21.4 to 2.6)  
rs2248137 
  
  
CC 97 53.4 (25.7) referent referent 0.24 
CG 129 51.2 (26.4) -2.2 +1.1 (-4.9 to 7.1)  
GG 60 45.4 (19.6) -8.0 -4.4 (-11.9 to 3.0)  
DBP 
  
  
  
  
  
  
  
  
  
  
  
  
rs16846876 
  
  
AA 138 54.9 (26.6) referent referent 0.015 
AT 127 47.7 (23.1) -7.2 -7.8 (-13.2 to -2.4)  
TT 15 47.5 (19.3) -7.4 -8.2 (-20.0 to 3.6)  
rs12512631 
  
  
TT 113 49.2 (24.9) referent referent 0.087 
CT 137 50.3 (24.2) +1.1 +2.6 (-3.2 to 8.4)  
CC 41 56.6 (27.4) +7.4 +7.2 (-1.0 to 15.4)  
rs2070741 
  
  
TT 240 50.2 (24.3) referent referent 0.038 
TG 46 53.7 (25.3) +3.5 +6.7 (-0.4 to 13.8)  
GG 1 118.0 (0) +67.8 +45.7 (2.6 to 88.8)  
rs2298849 
  
  
AA 175 50.1 (25.1) referent referent 0.47 
AG 101 51.8 (24.9) +1.7 +2.9 (-2.8 to 8.5)  
GG 12 52.2 (24.8) +2.1 +4.9 (-8.3 to 18.1)  
rs4588 
  
  
CC 160 56.0 (25.8) referent referent 0.005 
CA 113 45.0 (23.0) -11.0 -10.5 (-15.9 to -5.2)  
AA 16 36.6 (16.6) -22.4 -16.8 (-28.4 to -5.2)  
rs7041 
  
  
GG 91 58.8 (26.7) referent referent 0.053 
TG 132 47.9 (23.1) -10.9 -8.4 (-14.4 to -2.4)  
TT 63 47.1 (24.1) -11.7 -7.6 (-15.2 to 0.1)  
CYP27B1 
  
  
rs4646536 
  
  
AA 132 50.9 (25.9) referent referent 0.34 
AG 118 51.8 (25.2) +0.9 +0.1 (-5.6 to 5.7)  
GG 30 47.7 (21.4) -3.2 -4.4 (-13.3 to 4.6)  
CYP2R1 
  
  
  
  
  
  
rs10500804 
  
  
TT 104 54.4 (24.9) referent Referent 0.77 
GT 143 46.6 (24.3) -7.8 -8.1 (-13.8 to -2.4)  
GG 44 56.5 (25.3) +2.1 -1.2 (-9.1 to 6.7)  
rs2060793 
  
  
GG 107 50.3 (23.9) referent referent 0.84 
AG 129 52.5 (26.3) +2.2 +2.5 (-3.4 to 8.3)  
AA 41 45.7 (23.5) -4.6 -0.8 (-9.0 to 7.4)  
rs10766197 
  
  
GG 86 55.0 (24.9) referent referent 0.51 
AG 143 47.4 (24.6) -7.6 -9.4 (-15.5 to -3.4)  
AA 43 54.5 (25.4) -0.5 -2.8 (-11.0 to 5.5)  
DHCR7 
  
  
  
  
rs12785878 
  
  
TT 154 52.7 (25.3) referent referent 0.011 
GT 98 52.2 (25.1) -0.5 +1.4 (-4.5 to 7.3)  
GG 38 38.9 (21.3) -13.8 -12.2 (-21.5 to -2.8)  
rs3829251 
  
  
GG 220 50.1 (23.9) referent referent 0.96 
AG 69 52.6 (27.4) +2.5 +0.5 (-5.8 to 6.7)  
AA 2 42.0 (31.1) -8.1 +0.7 (-30.0 to 31.4)  
VDR 
  
   
rs10783219 
  
  
AA 136 50.8 (24.6) referent referent 0.28 
AT 116 50.4 (24.9) -0.4 -1.8 (-7.6 to 3.9)  
TT 34 49.3 (28.3) -1.5 -4.6 (-13.0 to 3.8)  
[1] Adjusted for sex, age, BMI, ethnicity, SEP, hours outdoors, vitamin D supplement consumption, quarter of sampling, Fitzpatrick skin-
type, smoking status, alcohol consumption, tanning bed use, recent sunny holiday, and BTS treatment step. After correction for 
multiple comparisons testing using the Benjamini & Hochberg method with a 5% false discovery rate, none of the above P values 
remained significant. 
Abbreviations: DBP: vitamin D binding protein, CYP2R1: cytochrome P450-2R1, CYP24A1: cytochrome P450-24A1, CYP27B1: 
cytochrome P450-27B1, DHCR7: 7-dehydrocholesterol reductase, VDR: vitamin D receptor, SNP: single nucleotide polymorphism, SD: 
standard deviation, CI: confidence interval. 
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Table 4. Clinical correlates of vitamin D status 
 
 Serum 25-
hydroxyvitamin D, 
nmol/L 
N Mean (SD) / 
Median (IQR) 1 
Univariate              
P value 2 
                                             Multivariable model 
 
  Beta coefficient,  
(95% CI) 3 
 
P value 4 
Antilog of beta 
coefficient, (95% CI) 3 
 
P value 4 
Asthma Control Test (ACT)  
score 
 
<25 40  19.5 (16.5 to 22) 0.87 - - 1.05 (0.96 to 1.16) 0.25 
25 – 49.9 122 20 (17 to 22)  -  1.02 (0.94 to 1.09)  
50 – 74.9 80 20 (17 to 22)  -  0.99 (0.92 to 1.07)  
≥ 75 55  20 (17 to 22)  -  referent  
% Predicted Forced  
Expiratory Volume in 1  
second (FEV1) 
 
<25 40  85.07 (17.60) 0.48 -1.11 (-8.67 to 6.45) 0.75 - - 
25 – 49.9 122 89.55 (21.90)  +1.30 (-4.44 to 7.03)  -  
50 – 74.9 80 90.33 (15.99)  +1.74 (-4.48 to 7.96)  -  
≥ 75 55  90.59 (17.02)  referent  -  
% Predicted Forced Vital 
Capacity (FVC) 
<25 40  0.98 (0.13) 0.079 -0.01 (-0.07 to 0.05) 0.81 - - 
25 – 49.9 122 1.04 (0.18)  +0.01 (-0.04 to 0.06)  -  
50 – 74.9 80 1.04 (0.15)  +0.00 (-0.05 to 0.05)  -  
≥ 75 55  1.07 (0.13)  referent  -  
Inhaled corticosteroid 
(ICS) dose in 
beclometasone 
equivalents, µg 5 
<25 40 400 (400 to 500) 0.87 - - 0.98 (0.72 to 1.34) 0.93 
25 – 49.9 120 400 (200 to 800)  -  1.00 (0.79 to 1.27)  
50 – 74.9 80 400 (200 to 700)  -  1.00 (0.77 to 1.29)  
≥ 75 54 400 (200 to 800)  -  referent  
Fractional exhaled nitric 
oxide (FeNO), ppb 
<25 40  30 (20.5 to 42) 0.55 - - 1.04 (0.80 to 1.35) 0.84 
25 – 49.9 120 29 (20 to 44.5)  -  1.10 (0.90 to 1.34)  
50 – 74.9 80 31 (19 to 45)  -  1.13 (0.91 to 1.40)  
≥ 75 54  24.5 (18 to 37)  -  referent  
% Eosinophils in induced 
sputum 
<50 19 1.50 (0.63 to 4.42) 0.97 - - 1.03 (0.58 to 1.84) 0.91 
≥ 50 16 1.50 (0.63 to 3.25)  -  referent  
 
[1] Mean values and standard deviations reported for normally distributed outcome data; median values and inter-quartile ranges reported for non-normally 
distributed outcome data 
[2] Univariate analysis method: One-way ANOVA test for normally distributed outcome data; Kruskal-Wallis test for non-normally distributed outcome data.  
[3] Beta coefficients and 95% confidence intervals reported for normally distributed outcome data; antilog of beta coefficients reported for log transformed outcome 
data 
[4] ACT, % predicted FEV1, % predicted FVC, ICS, and FeNO adjusted for sex, age, BMI, ethnicity, SEP, smoking status, alcohol consumption, influenza vaccination, and 
pneumonia vaccination; % eosinophils in induced sputum adjusted for sex, age, BMI, and FEV1/FVC ratio. All adjusted p values are for trend. 
 [5] 1µg beclometasone assumed equivalent to 1µg budesonide, 0.5 mcg fluticasone dipropionate and 0.75 mcg ciclesonide 
Definitions: CI, confidence interval; IQR, inter-quartile range; SD, standard deviation; ppb, parts per billion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
